We delivered revenue at the high end of our guidance range and exceeded the top end of our Adjusted EBITDA and EPS range. Our revenue growth was driven by our acute inpatient psychiatric facilities, with 14% growth compared to last year as we increased inpatient volumes by 6.2%. The increase in volumes across Acadia reflects the continued strong demand for our services. Our revenue growth and strong focus on operational improvements and efficiencies at every level of the organization drove Adjusted EBITDA to $144.2 million, $7.2 million above the high end of our guidance.
Our good start in quarter one is allowing us to raise our full-year Adjusted EBITDA guidance by $5 million at the midpoint. Todd will walk through the financial results and our guidance in more detail. These investments expand access to care and increase the number of patients we can serve each day. The demand is there, and our goal is to meet that demand with high-quality patient care and ensure that we eliminate barriers for treatment through prompt response times.
As a result of this increased focus, this group's revenue and Adjusted EBITDA results in quarter one were ahead of our expectations. We remain confident in this group delivering on $200 million of Adjusted EBITDA growth relative to 2025. While we are reducing our capital investment by over $300 million compared to 2025, we are finalizing investments in these new JV facilities while also adding beds to existing facilities. These tools help us make more informed operational decisions and deploy resources more effectively across facilities.
| Metric | Period | Current guidance |
|---|---|---|
| Full-year Adjusted EBITDA | FY2026 | $580M-$615M (raised $5M at midpoint) |
| Full-year Adjusted EPS | FY2026 | $1.35-$1.60 (raised $0.05) |
| Full-year revenue | FY2026 | $3.37B-$3.45B (unchanged) |
| Q2 revenue | Q2 2026 | $835M-$850M (newly provided) |
| Q2 Adjusted EBITDA | Q2 2026 | $142M-$152M (newly provided) |
| Q2 Adjusted EPS | Q2 2026 | $0.30-$0.40 (newly provided) |
| Full-year startup losses | FY2026 | $47M-$51M (lowered top end by $2M) |
| Metric | YoY | Note |
|---|---|---|
| Total revenue | +7.6% to $828.8M | growth led by acute (+14.2%) and RTC (+6.3%) businesses, plus Ohio and Tennessee supplemental payments not in prior-year Q1 |
| Same-facility revenue | +7.3% | 5.6% increase in revenue per patient day and 1.6% increase in patient days |
| Adjusted EBITDA | +7.5% to $144.2M | strong acute performance, outperformance of new facilities opened since 2023, and better-than-planned cost efficiencies at corporate and facilities |
| Specialty revenue | -6.5% | Pennsylvania challenges from New York's out-of-state Medicaid decision and 2025 specialty facility closures |
| CTC revenue | +2.5% | growth slowed sequentially due to severe winter weather closing certain centers |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| New facility ramp / startup losses | $14M Q1 forecast; facilities not ramping as quickly as expected | $12M actual, $2M better; each post-2023 facility now has a clear action plan | Improving |
| Bad debts and denials | thought to be stabilizing in Q4 | ran a little hotter than expected, broad-based, factored into full-year guide | Worsening |
| Staff retention | improving trend | improved for eighth consecutive quarter | Improving |
| Pennsylvania / New York Medicaid headwind | $25M-$30M annual EBITDA impact expected | specialty mitigated a portion; backfilling via New Jersey, Maryland and Pennsylvania referrals | Improving |
| Capital discipline | record expansion period | reducing capital investment over $300M vs 2025; CapEx of $255M-$280M for 2026 | Declining spend |